Bridgefront Capital, LLC Abb Vie Inc. Transaction History

Bridgefront Capital, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$133.59 - $154.65 $733,409 - $849,028	-5,490 Reduced 53.58%	4,757 $709,000
Q2 2023 Aug 14, 2023	BUY	$132.51 - $164.9 $1.36 Million - $1.69 Million	10,247 New	10,247 $1.38 Million
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $461,817 - $553,839	3,339 New	3,339 $539,000
Q1 2022 May 13, 2022	SELL	$131.98 - $163.75 $608,823 - $755,378	-4,613 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$107.43 - $135.93 $495,574 - $627,045	4,613 New	4,613 $625,000
Q3 2021 Nov 12, 2021	SELL	$106.4 - $120.78 $352,077 - $399,661	-3,309 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$105.21 - $117.21 $348,139 - $387,847	3,309 New	3,309 $373,000
Q1 2021 May 17, 2021	SELL	$102.3 - $112.62 $830,062 - $913,798	-8,114 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$80.49 - $108.67 $653,095 - $881,748	8,114 New	8,114 $869,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgefront Capital, LLC with notifications on news.